<DOC>
	<DOCNO>NCT02193308</DOCNO>
	<brief_summary>To demonstrate bioequivalence 80 mg telmisartan / 10 mg amlodipine fix dose combination ( FDC ) vs. monocomponents</brief_summary>
	<brief_title>Bioequivalence Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test 2 . Age ≥18 ≤55 year 3 . BMI ≥18.5 BMI ≤29.9 kg/m2 ( Body Mass Index ) 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance 2 . Any evidence clinically relevant concomitant disease 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 4 . Surgery gastrointestinal tract ( except appendectomy ) 5 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 6 . History relevant orthostatic hypotension , faint spell blackouts 7 . Chronic relevant acute infection 8 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) 9 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial 10 . Use drug might reasonably influence result trial ( especially unspecific induce agent like St.John´s wort ( Hypericum perforatum ) inhibitor like cimetidine ) prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial 11 . Participation another trial investigational drug within two month prior administration trial 12 . Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) 13 . Inability refrain smoke 24 hour prior dose trial 14 . Alcohol abuse inability stop alcoholic beverage 24 hour prior dose trial 15 . Drug abuse 16 . Blood donation ( 100 mL within four week prior administration trial ) 17 . Excessive physical activity ( within one week prior administration trial ) 18 . Any laboratory value outside reference range clinical relevance 19 . Inability comply dietary regimen trial site 20 . A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) 21 . A history additional risk factor Torsade de Pointes ( e.g. , heart failure , hyperkalemia , hypokalemia , family history Long QT Syndrome ) 22 . Any history relevant low blood pressure 23 . Supine blood pressure screen systolic &lt; 110 mm Hg diastolic &lt; 60 mm Hg 24 . History urticaria 25 . History angioneurotic edema 26 . Pregnancy / positive pregnancy test , plan become pregnant study within 1 month study completion 27 . No adequate contraception study 1 month study completion , i.e . implant , injectables , combine oral contraceptive , intrauterine device , sexual abstinence ( least 1 month prior enrolment ) , vasectomised partner ( vasectomy perform least 1 year prior enrolment ) , surgical sterilisation ( incl . hysterectomy ) . Females , vasectomise partner , sexually abstinent surgically sterile ask additionally use barrier contraception method ( e.g . condom , diaphragm spermicide ) 28 . Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>